Phaseline

Companies › Actimed Therapeutics

Actimed Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pindolol (ACM-001)
Beta-1 adrenergic receptor partial agonist; Beta-2 adrenergic receptor partial agonist
ADRB1, ADRB2Phase 2ObesityMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07101939Pindolol (ACM-001)Phase 2ObesityMetabolic and endocrineMar 2027

Targets

ADRB1 (1) ADRB2 (1)

Companies with the same targets

Chiesi Farmaceutici AstraZeneca ARS Pharmaceuticals EyeD Pharma Acer Therapeutics GSK Tecnoquimicas Lunan Better Pharmaceutical Polarean Novartis

Companies built like this

Veru Skye Bioscience PolTREG Protalix Urovant Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.